Alyson Harty
Adult Health · New York, NYNPI 1285253518
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Gilead accounts for 67.5% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $23,370, 3.4 times the $6,894 reported in 2021. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $286.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$44K
- Madrigal Pharmaceuticals$20K
- AbbVie$311
- Ipsen Biopharmaceuticals, Inc$243
- Intercept Pharmaceuticals, Inc.$227
- Alcresta Therapeutics, Inc.$125
- plus $80 from 3 others
What the payments were for
- Consulting fees$8,24313%
- Speaking & faculty fees$36,05055%
- Travel & lodging$13,82421%
- Food & beverage$7,09411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 161 | $44,007 |
| Madrigal Pharmaceuticals | 45 | $20,220 |
| AbbVie | 11 | $311 |
| Ipsen Biopharmaceuticals, Inc | 5 | $243 |
| Intercept Pharmaceuticals, Inc. | 2 | $227 |
| Alcresta Therapeutics, Inc. | 1 | $125 |
| Orphalan Inc | 1 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
| Mirum Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$65,211 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 99 | $355,726 |
| EpclusaSofosbuvir/Velpatasvir | 14 | $298,513 |
| OcalivaObeticholic Acid | 27 | $240,615 |
| VemlidyTenofovir Alafenamide | 103 | $147,633 |
| Ursodiol | 207 | $28,978 |
| EliquisApixaban | 27 | $14,800 |
| Entecavir | 69 | $7,834 |
| VascepaIcosapent Ethyl | 20 | $6,787 |
| Lactulose | 63 | $2,683 |
| Famotidine | 138 | $1,619 |
| Pantoprazole Sodium | 117 | $1,341 |
| Nadolol | 28 | $1,336 |
| Tenofovir Disoproxil Fumarate | 13 | $614 |
| Omeprazole | 63 | $562 |
| Carvedilol | 72 | $454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $44,007 | $446,146117 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $227 | $240,61527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in New York
- Donna CatameroNew York$279K
- Laura GraaflandNew York$51K
- Allysa SaggeseNew York$49K
- Juliet EscalonNew York$46K
- Teshmanie RampersaudNew York$23K
- Elizabeth SavageNew York$20K
- Libby LevineNew York$19K
- Hyo Jin KangNew York$19K
- Monica RicheyNew York$19K
- Vincent Guilamo-RamosNew York$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.